How Much Did Immunis Raise?
Funding & Key Investors

Immunis, a biotechnology firm at the forefront of regenerative medicine, has successfully secured a major strategic investment, bringing its total capital raised to $35M. This latest infusion of $25M underscores the market's growing confidence in the company's proprietary approach to addressing age-related immune decline. By leveraging a novel method for cultivating human stem cells, Immunis is positioning itself as a critical player in the longevity sector, moving beyond theoretical research into active clinical validation.

The company's trajectory, marked by a series of strategic financing rounds, reflects a robust growth phase. As Immunis transitions from early-stage development to more advanced clinical milestones, this capital injection provides the necessary runway to accelerate its primary therapeutic programs. The firm's ability to attract high-caliber institutional backing highlights the scalability of its platform and the potential for its immune-modulating products to redefine standard-of-care treatments for age-associated conditions.